Oral  ||| S:0 E:5 ||| JJ
supplementation  ||| S:5 E:21 ||| NN
with  ||| S:21 E:26 ||| IN
superoxide  ||| S:26 E:37 ||| JJ
dismutase  ||| S:37 E:47 ||| NN
in  ||| S:47 E:50 ||| IN
Standardbred  ||| S:50 E:63 ||| NNP
trotters  ||| S:63 E:72 ||| NN
in  ||| S:72 E:75 ||| IN
training ||| S:75 E:83 ||| NN
:  ||| S:83 E:85 ||| :
a  ||| S:85 E:87 ||| DT
double-blind  ||| S:87 E:100 ||| JJ
placebo-controlled  ||| S:100 E:119 ||| JJ
study  ||| S:119 E:125 ||| NN
Intense  ||| S:125 E:133 ||| JJ
physical  ||| S:133 E:142 ||| JJ
exercise  ||| S:142 E:151 ||| NN
produces  ||| S:151 E:160 ||| VBZ
an  ||| S:160 E:163 ||| DT
excess  ||| S:163 E:170 ||| NN
of  ||| S:170 E:173 ||| IN
reactive  ||| S:173 E:182 ||| JJ
oxygen  ||| S:182 E:189 ||| NN
species  ||| S:189 E:197 ||| NNS
which  ||| S:197 E:203 ||| WDT
can  ||| S:203 E:207 ||| MD
disturb  ||| S:207 E:215 ||| VB
the  ||| S:215 E:219 ||| DT
antioxidant ||| S:219 E:230 ||| JJ
/ ||| S:230 E:231 ||| CD
oxidant  ||| S:231 E:239 ||| JJ
balance  ||| S:239 E:247 ||| NN
of  ||| S:247 E:250 ||| IN
the  ||| S:250 E:254 ||| DT
horse  ||| S:254 E:260 ||| NN
in  ||| S:260 E:263 ||| IN
training ||| S:263 E:271 ||| NN
.  ||| S:271 E:273 ||| .
Several  ||| S:273 E:281 ||| JJ
classes  ||| S:281 E:289 ||| NNS
of  ||| S:289 E:292 ||| IN
antioxidant  ||| S:292 E:304 ||| JJ
dietary  ||| S:304 E:312 ||| JJ
compounds  ||| S:312 E:322 ||| NNS
have  ||| S:322 E:327 ||| VBP
been  ||| S:327 E:332 ||| VBN
suggested  ||| S:332 E:342 ||| VBN
to  ||| S:342 E:345 ||| TO
provide  ||| S:345 E:353 ||| VB
health  ||| S:353 E:360 ||| NN
benefits  ||| S:360 E:369 ||| NNS
and  ||| S:369 E:373 ||| CC
there  ||| S:373 E:379 ||| EX
is  ||| S:379 E:382 ||| VBZ
evidence  ||| S:382 E:391 ||| NN
that  ||| S:391 E:396 ||| IN
consumption  ||| S:396 E:408 ||| NN
of  ||| S:408 E:411 ||| IN
these  ||| S:411 E:417 ||| DT
products  ||| S:417 E:426 ||| NNS
leads  ||| S:426 E:432 ||| VBZ
to  ||| S:432 E:435 ||| TO
a  ||| S:435 E:437 ||| DT
reduction  ||| S:437 E:447 ||| NN
in  ||| S:447 E:450 ||| IN
the  ||| S:450 E:454 ||| DT
expression  ||| S:454 E:465 ||| NN
of  ||| S:465 E:468 ||| IN
various  ||| S:468 E:476 ||| JJ
pro-inflammatory  ||| S:476 E:493 ||| JJ
and ||| S:493 E:496 ||| CC
/ ||| S:496 E:497 ||| NNP
or  ||| S:497 E:500 ||| CC
oxidative  ||| S:500 E:510 ||| JJ
stress  ||| S:510 E:517 ||| NN
biomarkers ||| S:517 E:527 ||| NN
.  ||| S:527 E:529 ||| .
The  ||| S:529 E:533 ||| DT
recent  ||| S:533 E:540 ||| JJ
development  ||| S:540 E:552 ||| NN
of  ||| S:552 E:555 ||| IN
a  ||| S:555 E:557 ||| DT
new  ||| S:557 E:561 ||| JJ
galenic  ||| S:561 E:569 ||| JJ
system  ||| S:569 E:576 ||| NN
allows  ||| S:576 E:583 ||| VBZ
the  ||| S:583 E:587 ||| DT
oral  ||| S:587 E:592 ||| JJ
delivery  ||| S:592 E:601 ||| NN
of  ||| S:601 E:604 ||| IN
the  ||| S:604 E:608 ||| DT
antioxidant  ||| S:608 E:620 ||| JJ
enzyme ||| S:620 E:626 ||| NN
:  ||| S:626 E:628 ||| :
superoxide  ||| S:628 E:639 ||| FW
dismutase  ||| S:639 E:649 ||| FW
( ||| S:649 E:650 ||| -LRB-
SOD ||| S:650 E:653 ||| NNP
) ||| S:653 E:654 ||| -RRB-
.  ||| S:654 E:656 ||| .
This  ||| S:656 E:661 ||| DT
has  ||| S:661 E:665 ||| VBZ
been  ||| S:665 E:670 ||| VBN
developed  ||| S:670 E:680 ||| VBN
from  ||| S:680 E:685 ||| IN
a  ||| S:685 E:687 ||| DT
specific  ||| S:687 E:696 ||| JJ
melon  ||| S:696 E:702 ||| JJ
variety  ||| S:702 E:710 ||| NN
with  ||| S:710 E:715 ||| IN
a  ||| S:715 E:717 ||| DT
particularly  ||| S:717 E:730 ||| RB
high  ||| S:730 E:735 ||| JJ
SOD  ||| S:735 E:739 ||| NNP
activity ||| S:739 E:747 ||| NN
.  ||| S:747 E:749 ||| .
To  ||| S:749 E:752 ||| TO
study  ||| S:752 E:758 ||| VB
the  ||| S:758 E:762 ||| DT
influence  ||| S:762 E:772 ||| NN
of  ||| S:772 E:775 ||| IN
an  ||| S:775 E:778 ||| DT
oral  ||| S:778 E:783 ||| JJ
supplementation  ||| S:783 E:799 ||| NN
with  ||| S:799 E:804 ||| IN
an  ||| S:804 E:807 ||| DT
encapsulated  ||| S:807 E:820 ||| JJ
melon  ||| S:820 E:826 ||| JJ
rich  ||| S:826 E:831 ||| JJ
in  ||| S:831 E:834 ||| IN
SOD  ||| S:834 E:838 ||| NNP
on  ||| S:838 E:841 ||| IN
muscular  ||| S:841 E:850 ||| NN
and  ||| S:850 E:854 ||| CC
antioxidant  ||| S:854 E:866 ||| JJ
balance  ||| S:866 E:874 ||| NN
variables  ||| S:874 E:884 ||| NNS
in  ||| S:884 E:887 ||| IN
a  ||| S:887 E:889 ||| DT
population  ||| S:889 E:900 ||| NN
of  ||| S:900 E:903 ||| IN
Standardbreds  ||| S:903 E:917 ||| NNP
in  ||| S:917 E:920 ||| IN
training ||| S:920 E:928 ||| NN
.  ||| S:928 E:930 ||| .
Twenty-four  ||| S:930 E:942 ||| NNP
Standardbreds  ||| S:942 E:956 ||| NNP
in  ||| S:956 E:959 ||| IN
training  ||| S:959 E:968 ||| NN
were  ||| S:968 E:973 ||| VBD
paired  ||| S:973 E:980 ||| VBN
by  ||| S:980 E:983 ||| IN
age ||| S:983 E:986 ||| NN
,  ||| S:986 E:988 ||| ,
sex  ||| S:988 E:992 ||| NN
and  ||| S:992 E:996 ||| CC
training  ||| S:996 E:1005 ||| NN
level ||| S:1005 E:1010 ||| NN
.  ||| S:1010 E:1012 ||| .
They  ||| S:1012 E:1017 ||| PRP
were  ||| S:1017 E:1022 ||| VBD
randomly  ||| S:1022 E:1031 ||| RB
split  ||| S:1031 E:1037 ||| VBN
into  ||| S:1037 E:1042 ||| IN
2  ||| S:1042 E:1044 ||| CD
groups ||| S:1044 E:1050 ||| NNS
:  ||| S:1050 E:1052 ||| :
SOD  ||| S:1052 E:1056 ||| NNP
group  ||| S:1056 E:1062 ||| NN
( ||| S:1062 E:1063 ||| -LRB-
520  ||| S:1063 E:1067 ||| CD
iu ||| S:1067 E:1069 ||| CD
/ ||| S:1069 E:1070 ||| CD
day ||| S:1070 E:1073 ||| NN
)  ||| S:1073 E:1075 ||| -RRB-
and  ||| S:1075 E:1079 ||| CC
placebo  ||| S:1079 E:1087 ||| JJ
group ||| S:1087 E:1092 ||| NN
.  ||| S:1092 E:1094 ||| .
At  ||| S:1094 E:1097 ||| IN
the  ||| S:1097 E:1101 ||| DT
beginning  ||| S:1101 E:1111 ||| NN
of  ||| S:1111 E:1114 ||| IN
the  ||| S:1114 E:1118 ||| DT
study  ||| S:1118 E:1124 ||| NN
( ||| S:1124 E:1125 ||| -LRB-
T0 ||| S:1125 E:1127 ||| NNP
)  ||| S:1127 E:1129 ||| -RRB-
and  ||| S:1129 E:1133 ||| CC
after  ||| S:1133 E:1139 ||| IN
30  ||| S:1139 E:1142 ||| CD
days  ||| S:1142 E:1147 ||| NNS
( ||| S:1147 E:1148 ||| -LRB-
T30 ||| S:1148 E:1151 ||| NNP
)  ||| S:1151 E:1153 ||| -RRB-
and  ||| S:1153 E:1157 ||| CC
60  ||| S:1157 E:1160 ||| CD
days  ||| S:1160 E:1165 ||| NNS
( ||| S:1165 E:1166 ||| -LRB-
T60 ||| S:1166 E:1169 ||| NNP
)  ||| S:1169 E:1171 ||| -RRB-
of  ||| S:1171 E:1174 ||| IN
supplementation ||| S:1174 E:1189 ||| NN
,  ||| S:1189 E:1191 ||| ,
physiological  ||| S:1191 E:1205 ||| JJ
response  ||| S:1205 E:1214 ||| NN
during  ||| S:1214 E:1221 ||| IN
a  ||| S:1221 E:1223 ||| DT
standardised  ||| S:1223 E:1236 ||| JJ
exercise  ||| S:1236 E:1245 ||| NN
test ||| S:1245 E:1249 ||| NN
,  ||| S:1249 E:1251 ||| ,
plasma  ||| S:1251 E:1258 ||| JJ
muscular  ||| S:1258 E:1267 ||| JJ
enzymes  ||| S:1267 E:1275 ||| NN
at  ||| S:1275 E:1278 ||| IN
rest  ||| S:1278 E:1283 ||| NN
and  ||| S:1283 E:1287 ||| CC
post  ||| S:1287 E:1292 ||| NN
exercise  ||| S:1292 E:1301 ||| NN
( ||| S:1301 E:1302 ||| -LRB-
creatine  ||| S:1302 E:1311 ||| FW
kinase ||| S:1311 E:1317 ||| FW
) ||| S:1317 E:1318 ||| -RRB-
,  ||| S:1318 E:1320 ||| ,
oxidative  ||| S:1320 E:1330 ||| JJ
stress  ||| S:1330 E:1337 ||| NN
markers  ||| S:1337 E:1345 ||| NNS
( ||| S:1345 E:1346 ||| -LRB-
erythrocyte  ||| S:1346 E:1358 ||| UH
SOD ||| S:1358 E:1361 ||| UH
)  ||| S:1361 E:1363 ||| -RRB-
and  ||| S:1363 E:1367 ||| CC
blood  ||| S:1367 E:1373 ||| NN
resistance  ||| S:1373 E:1384 ||| NN
to  ||| S:1384 E:1387 ||| TO
haemolysis  ||| S:1387 E:1398 ||| VB
( ||| S:1398 E:1399 ||| -LRB-
KRL  ||| S:1399 E:1403 ||| NNP
test ||| S:1403 E:1407 ||| NN
)  ||| S:1407 E:1409 ||| -RRB-
were  ||| S:1409 E:1414 ||| VBD
assessed ||| S:1414 E:1422 ||| VBN
.  ||| S:1422 E:1424 ||| .
Analysis  ||| S:1424 E:1433 ||| NN
of  ||| S:1433 E:1436 ||| IN
variance  ||| S:1436 E:1445 ||| NN
of  ||| S:1445 E:1448 ||| IN
time ||| S:1448 E:1452 ||| NN
,  ||| S:1452 E:1454 ||| ,
treatment  ||| S:1454 E:1464 ||| NN
and  ||| S:1464 E:1468 ||| CC
interaction  ||| S:1468 E:1480 ||| JJ
time  ||| S:1480 E:1485 ||| NN
x  ||| S:1485 E:1487 ||| SYM
treatment  ||| S:1487 E:1497 ||| NN
was  ||| S:1497 E:1501 ||| VBD
calculated ||| S:1501 E:1511 ||| VBN
.  ||| S:1511 E:1513 ||| .
Between  ||| S:1513 E:1521 ||| IN
T0  ||| S:1521 E:1524 ||| NNP
and  ||| S:1524 E:1528 ||| CC
T60 ||| S:1528 E:1531 ||| NNP
,  ||| S:1531 E:1533 ||| ,
in  ||| S:1533 E:1536 ||| IN
contrast  ||| S:1536 E:1545 ||| NN
with  ||| S:1545 E:1550 ||| IN
placebo  ||| S:1550 E:1558 ||| JJ
group ||| S:1558 E:1563 ||| NN
,  ||| S:1563 E:1565 ||| ,
a  ||| S:1565 E:1567 ||| DT
significant  ||| S:1567 E:1579 ||| JJ
increase  ||| S:1579 E:1588 ||| NN
in  ||| S:1588 E:1591 ||| IN
the  ||| S:1591 E:1595 ||| DT
plasma  ||| S:1595 E:1602 ||| JJ
resistance  ||| S:1602 E:1613 ||| NN
to  ||| S:1613 E:1616 ||| TO
haemolysis  ||| S:1616 E:1627 ||| VB
in  ||| S:1627 E:1630 ||| IN
the  ||| S:1630 E:1634 ||| DT
SOD  ||| S:1634 E:1638 ||| NNP
group  ||| S:1638 E:1644 ||| NN
was  ||| S:1644 E:1648 ||| VBD
observed  ||| S:1648 E:1657 ||| VBN
and  ||| S:1657 E:1661 ||| CC
it  ||| S:1661 E:1664 ||| PRP
was  ||| S:1664 E:1668 ||| VBD
significantly  ||| S:1668 E:1682 ||| RB
higher  ||| S:1682 E:1689 ||| JJR
( ||| S:1689 E:1690 ||| -LRB-
P  ||| S:1690 E:1692 ||| NNP
< ||| S:1692 E:1694 ||| SYM
0.05 ||| S:1694 E:1698 ||| CD
)  ||| S:1698 E:1700 ||| -RRB-
in  ||| S:1700 E:1703 ||| IN
the  ||| S:1703 E:1707 ||| DT
SOD  ||| S:1707 E:1711 ||| NNP
group  ||| S:1711 E:1717 ||| NN
than  ||| S:1717 E:1722 ||| IN
in  ||| S:1722 E:1725 ||| IN
the  ||| S:1725 E:1729 ||| DT
placebo  ||| S:1729 E:1737 ||| JJ
group  ||| S:1737 E:1743 ||| NN
on  ||| S:1743 E:1746 ||| IN
T60 ||| S:1746 E:1749 ||| CD
.  ||| S:1749 E:1751 ||| .
Between  ||| S:1751 E:1759 ||| IN
T0  ||| S:1759 E:1762 ||| NNP
and  ||| S:1762 E:1766 ||| CC
T60 ||| S:1766 E:1769 ||| NNP
,  ||| S:1769 E:1771 ||| ,
resting  ||| S:1771 E:1779 ||| VBG
CK  ||| S:1779 E:1782 ||| NNP
remained  ||| S:1782 E:1791 ||| VBD
constant  ||| S:1791 E:1800 ||| JJ
in  ||| S:1800 E:1803 ||| IN
SOD  ||| S:1803 E:1807 ||| NNP
group  ||| S:1807 E:1813 ||| NN
whereas  ||| S:1813 E:1821 ||| IN
a  ||| S:1821 E:1823 ||| DT
significant  ||| S:1823 E:1835 ||| JJ
increase  ||| S:1835 E:1844 ||| NN
in  ||| S:1844 E:1847 ||| IN
plasma  ||| S:1847 E:1854 ||| JJ
CK  ||| S:1854 E:1857 ||| NN
in  ||| S:1857 E:1860 ||| IN
the  ||| S:1860 E:1864 ||| DT
placebo  ||| S:1864 E:1872 ||| JJ
group  ||| S:1872 E:1878 ||| NN
was  ||| S:1878 E:1882 ||| VBD
observed ||| S:1882 E:1890 ||| VBN
.  ||| S:1890 E:1892 ||| .
On  ||| S:1892 E:1895 ||| IN
T60 ||| S:1895 E:1898 ||| NNP
,  ||| S:1898 E:1900 ||| ,
the  ||| S:1900 E:1904 ||| DT
CK  ||| S:1904 E:1907 ||| NNP
level  ||| S:1907 E:1913 ||| NN
was  ||| S:1913 E:1917 ||| VBD
significantly  ||| S:1917 E:1931 ||| RB
lower  ||| S:1931 E:1937 ||| JJR
( ||| S:1937 E:1938 ||| -LRB-
P  ||| S:1938 E:1940 ||| NNP
< ||| S:1940 E:1942 ||| SYM
0.05 ||| S:1942 E:1946 ||| CD
)  ||| S:1946 E:1948 ||| -RRB-
in  ||| S:1948 E:1951 ||| IN
SOD  ||| S:1951 E:1955 ||| NNP
group  ||| S:1955 E:1961 ||| NN
than  ||| S:1961 E:1966 ||| IN
in  ||| S:1966 E:1969 ||| IN
the  ||| S:1969 E:1973 ||| DT
placebo  ||| S:1973 E:1981 ||| JJ
group ||| S:1981 E:1986 ||| NN
.  ||| S:1986 E:1988 ||| .
These  ||| S:1988 E:1994 ||| DT
results  ||| S:1994 E:2002 ||| NNS
suggest  ||| S:2002 E:2010 ||| VBP
that  ||| S:2010 E:2015 ||| IN
oral  ||| S:2015 E:2020 ||| JJ
SOD  ||| S:2020 E:2024 ||| NNP
supplementation  ||| S:2024 E:2040 ||| NN
might  ||| S:2040 E:2046 ||| MD
increase  ||| S:2046 E:2055 ||| VB
blood  ||| S:2055 E:2061 ||| NN
resistance  ||| S:2061 E:2072 ||| NN
to  ||| S:2072 E:2075 ||| TO
haemolysis  ||| S:2075 E:2086 ||| VB
and  ||| S:2086 E:2090 ||| CC
reduce  ||| S:2090 E:2097 ||| VB
the  ||| S:2097 E:2101 ||| DT
increase  ||| S:2101 E:2110 ||| NN
in  ||| S:2110 E:2113 ||| IN
muscular  ||| S:2113 E:2122 ||| JJ
membrane  ||| S:2122 E:2131 ||| NNS
permeability  ||| S:2131 E:2144 ||| VBP
induced  ||| S:2144 E:2152 ||| VBN
by  ||| S:2152 E:2155 ||| IN
training ||| S:2155 E:2163 ||| NN
.  ||| S:2163 E:2165 ||| .
